Scalper1 News
Shares of biotech Spark Therapeutics (ONCE) soared in heavy trading Monday after it reported positive late-stage trial data on its treatment for a rare eye disease. Spark said that SPK-RPE65, a gene therapy for a type of inherited retinal dystrophy (IRD), met the trial’s endpoint of improving functional vision compared with the control group. The drug also met Spark’s secondary endpoints based on light sensitivity and a mobility test for the first Scalper1 News
Scalper1 News